荷兰鹿特丹市长Ahmed Aboutaleb先生率代表团到访和铂医药

Mayor of Rotterdam Leads Delegation to Visit Harbour BioMed’s Shanghai Innovation Centre

（*Please scroll down for English news)

2019年6月11日，荷兰鹿特丹市长Ahmed Aboutaleb先生率代表团到访了和铂医药上海研发中心，作为鹿特丹-上海姐妹城市40周年的重要活动之一，来自荷兰鹿特丹市政厅、荷兰领事馆、荷兰外商投资局、鹿特丹创新中心、鹿特丹合作方以及荷兰伊拉斯姆斯医学中心的领导和朋友们参与了此次活动。与此同时，来自上海市人民政府外事办公室、上海市药监局、上海市张江科学城、上海市科创板人才服务处等政府部门的领导共同参与了以“合作推动生物医药全球化创新为主题”的讨论和交流。

和铂医药起源于鹿特丹。在和铂医药创立初期（2016年底）以现金加股权的方式收购了总部位于荷兰的Harbour Antibodies BV（成立于2006年）公司，由此获得抗体药物研发的“芯片技术”--全人源转基因小鼠抗体研发技术平台。以这一平台为基础， 和铂医药正在全球三个港口城市上海、鹿特丹和波士顿开展下一代肿瘤和免疫新药创新疗法的研发，打造专注于肿瘤免疫及免疫领域的新药研发管线。在鹿特丹，和铂医药创始科学家，英国皇家学院及荷兰皇家艺术和科学学院双院院士Frank Grosveld 博士带领和铂医药荷兰创新中心继续进行核心技术的升级与持续研发。

和铂医药是一家聚焦于免疫性疾病（包括免疫与肿瘤免疫）领域的全球化的生物制药公司，目前已有多个创新药物进入临床开发阶段，最快的已进入临床二期。公司利用其拥有全球专利的两个全人源抗体转基因小鼠平台（Harbour Mice™）研发针对肿瘤免疫和免疫性疾病的突破性创新疗法。和铂医药还通过与业务伙伴的多元化合作快速拓展其新药研发管线。更多信息，请访问 www.harbourbiomed.com。

Mayor of Rotterdam Leads Delegation to Visit Harbour BioMed’s Shanghai Innovation Centre

On 11th June 2019, Mr Ahmed Aboutaleb, the Mayor of Rotterdam in the Netherlands visited Harbour BioMed’s Shanghai Innovation Center with his delegation. This visit was part of a week-long trip to Shanghai on the occasion of the 40th-anniversary celebration for Rotterdam-Shanghai sister relationship.

The Mayor’s delegation consisted of members of the City of Rotterdam, Dutch Consulate in Shanghai, The Netherlands Foreign Investment Agency, Rotterdam Partners, InnovationQuarter, and Erasmus MC. Local dignitaries from Shanghai government including delegates of Foreign Affairs Office of Shanghai, Shanghai Municipal Drug Administration, Zhangjiang Science City and Talent Service Center of Science and Technology Innovation Board also joined the visit and participated in very active discussions around innovation in global biopharma through collaboration.

Over the last 40 years, Shanghai and Rotterdam have collaborated on several different projects in the field of Port, Maritime, Logistics, amongst others. This time the mayors are also focusing on Life-Sciences and Health as one of the key priorities for discussion. In line with this, the visit to HBM was focused on understanding what a mid-size startup biotech company looks like and what kind of ecosystem it takes to attract such companies to build a life-sciences hub in Rotterdam.

HBM has a long history with Rotterdam as it acquired the Dutch company Harbour Antibodies BV (established in 2006) at the end of 2016. By doing so, they gained the global patents for the use and out-licensing of the transgenic mouse platform capable of generating fully human monoclonal antibodies, now known as the Harbour Mice™. Using these platforms, HBM is developing the next-generation of therapies for cancer and immune-driven disorders with operations in three harbour cities across the world, Rotterdam, Boston and Shanghai. In Rotterdam, Dr Frank Grosveld, the founding scientist of Harbour Antibodies and member of the Royal Netherlands Academy of Arts and Sciences and Fellow of the Royal Society (UK), leads new developments both on the platform as well as targets identified by the global discovery teams.

“The Netherlands has contributed significantly to the life-science and healthcare industry due to its collaborations between academic institutions, industry and government institutions who promote the R&D through open dialogue and economic policies. HBM’s core technology originated in Rotterdam and is poised to deliver innovative medicines all over the world. We are privileged to have the opportunity to facilitate the evolution of the technology and its application toward meeting unmet patient needs” Jingsong Wang, MD PhD, Founder, Chairman and CEO of Harbour BioMed said.

Harbour BioMed is a global biopharmaceutical company developing innovative therapeutics in the fields of Immuno-Oncology and Inflammatory Diseases. The company’s discovery and development programs are centered around its two patented transgenic mouse platforms (Harbour Mice™) for generating fully human monoclonal antibodies. The company is building its proprietary pipeline through internal discovery research, collaboration with co-discovery and co-development partners, and acquisition of innovative preclinical and clinical stage assets that strategically fit its internal portfolio. For more information, visit www.harbourbiomed.com.